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Relationship Between Dietary Magnesium
Intake and Incident Heart Failure
Among Older Women: The WHI
Wen-Chih Wu
, MD, MPH; Mengna Huang, PhD; Tracey H. Taveira, PharmD; Mary B. Roberts, MS;
Lisa W. Martin, MD; Gregory A. Wellenius, ScD; Karen C. Johnson, MD; JoAnn E. Manson, MD, DrPH;
Simin Liu, ScD, MD; Charles B. Eaton, MD
BACKGROUND: Women represent a large proportion of the growing heart failure (HF) epidemic, yet data are lacking regarding
optimal dietary and lifestyle prevention strategies for them. Specifically, the association between magnesium intake and HF in
a multiracial cohort of women is uncertain.
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METHODS AND RESULTS: We included 97 725 postmenopausal women from the WHI (Women’s Health Initiative) observational
studies and placebo arms of the hormone trial. Magnesium intake was measured at baseline by a 122-item validated food-
frequency questionnaire and stratified into quartiles based on diet only, total intake (diet with supplements), and residual intake
(calibration by total energy). Incident hospitalized HF (2153 events, median follow-up 8.1 years) was adjudicated by medical
record abstraction. In Cox proportional hazards models, we evaluated the association between magnesium intake and HF adjusting for potential confounders. Analyses were repeated on a subcohort (n=18 745; median-follow-up, 13.2 years) for whom
HF cases were subclassified into preserved ejection fraction (526 events), reduced ejection fraction (291 events) or unknown
(168 events). Most women were white (85%) with a mean age of 63. Compared with the highest quartile of magnesium intake,
women in the lowest quartile had an increased risk of incident HF, with adjusted hazard ratios of 1.32 (95% CI, 1.02–1.71) for
diet only (P trend=0.03), 1.26 (95% CI, 1.03–1.56) for total intake, and 1.31 (95% CI, 1.02–1.67) for residual intake. Results
did not significantly vary by race. Subcohort analyses showed low residual magnesium intake was associated with HF with
reduced ejection fraction (hazard ratio, 1.81, lowest versus highest quartile; 95% CI, 1.08–3.05) but not HF with preserved
ejection fraction.
CONCLUSIONS: Low magnesium intake in a multiracial cohort of postmenopausal women was associated with a higher risk of
incident HF, especially HF with reduced ejection fraction.
Key Words: heart failure with preserved ejection fraction ■ heart failure with reduced ejection fraction ■ residual method

■ total magnesium

I

n 2015, it was estimated that 5.7 million individuals
over the age of 20 in the United States have been diagnosed with heart failure (HF).1 Of those diagnosed
with HF, 3 million were women. It is estimated that
455 000 new HF cases will be diagnosed in women
older than 45 years each year.1 However, data are

lacking regarding optimal dietary and lifestyle prevention strategies for HF in this population.
Low serum and dietary magnesium have been
associated with risk factors of HF, such as coronary
heart disease,2 insulin resistance,3 type 2 diabetes
mellitus,4 hypertension,5,6 and atrial fibrillation.7 Dietary
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CLINICAL PERSPECTIVE
What Is New?

• The association between magnesium intake and
heart failure in a multiracial cohort of women is
unknown.
• This study showed that lower dietary intake of
magnesium was associated with higher incidence rates of hospitalization for heart failure in
postmenopausal women.
• In subgroup analyses, low dietary magnesium
was associated with incident hospitalization for
heart failure with reduced ejection fraction but
not preserved ejection fraction.

What Are the Clinical Implications?

• These results suggest that ≈75% of postmenopausal women in this cohort have a median
magnesium intake below US Recommended
Daily Allowance levels, and a quarter of them
are at increased risk of incident heart failure
based on their dietary magnesium intake.

ejection fraction [HFrEF]) is unknown and would be important to understand potential mechanistic pathways
of this relationship.
Because risk factors and the incidence and type of
HF vary by women of different race,11 understanding
the association between magnesium intake and the
risk of developing HF and its subtypes in a multiracial
cohort of women represents a novel and potentially
useful approach to identifying women at increased
risk for target prevention. The purpose of this study
is to examine the relationship between dietary magnesium and incident HF in the WHI (Women’s Health
Initiative) study. We hypothesize that low dietary magnesium intake will be associated with an increased
risk of incident hospitalizations for HF. The prospective design of the WHI, the long follow-up, and
availability of comprehensive dietary information and
lifestyle factors in this clinically well-
characterized
multiracial population allow us the unique opportunity
to rigorously test this hypothesis in postmenopausal
women.

METHODS
Nonstandard Abbreviations and Acronyms
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ARIC
Atherosclerosis Risk in Communities
BMI
body mass index
HF
heart failure
HFpEF	
heart failure with preserved ejection
fraction
HFrEF	
heart failure with reduced ejection
fraction
HR
hazard ratio
JHS
Jackson Heart Study
LV
left ventricular
OS
observational study
WHI
Women’s Health Initiative.

magnesium intake is also associated with HF hospitalizations in African-Americans in the Jackson Heart
Study8 and could potentially be a target for lifestyle
modification and HF prevention, as >80% of older
adults in the United States are not meeting dietary
magnesium recommendations.9 However, it is known
that racial differences exist in magnesium intake,9 and
magnesium intake requirements are different for men
and women.10 Yet data are lacking on the relationship
between dietary magnesium and HF in a multiracial
cohort of women. Moreover, the relationship between
magnesium intake and the type of HF (HF with preserved ejection fraction [HFpEF] or HF with reduced

Because of the sensitive nature of the data collected
for this study, requests to access the data set from
qualified researchers trained in human subject confidentiality protocols may be sent to the WHI at https://
www.whi.org/researchers/data/Pages/Home.aspx.

Study Population
The WHI recruited a total of 161 808 postmenopausal women aged 50 to 79 years at 40 clinical centers
across the United States between 1993 and 1998,
including a cohort of 93 676 women in a prospective observational study (OS) and 68 133 women in
≥1 of the following 3 clinical trials: hormone therapy,
calcium and vitamin D, or dietary modification trial.12
The calcium and vitamin D trial participants were
recruited from the hormone therapy and dietary
modification trials. The primary analysis included
participants of the OS and control arm of the hormone therapy trial who completed baseline physical examination, demographic, medical history, and
dietary questionnaires. Overall, baseline characteristics of participants from the OS and the hormone
therapy trials were grossly similar except for college
education (43% versus 32%), income <$20 000 per
annum (14% versus 21%), mean body mass index
(BMI; 27.2±5.8 versus 28.4±5.9), recreational physical activity (13.8±14.4 versus 11.9±13.8 metabolic
equivalents/week), diabetes mellitus prevalence
(3.8% versus 5.2%), and multivitamin use (42% versus 36.0%), respectively. Participants in the dietary
modification trial were excluded from the analysis,
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as baseline diet would not reflect a stable diet, and
because of potential selection bias of a high percentage of dietary fat as an inclusion criterion for
the dietary modification trial. Participants with HF
at baseline were excluded as established by self-
reporting on the eligibility screening and baseline
medical history questionnaires, in which participants
were asked to self-identify if they have ever been
told by a doctor that they have HF or congestive HF.
Participants were also excluded if they had a baseline energy intake outside the range of 600 kcal to
5000 kcal/day because of potential misclassification
(Figure 1).13 Given that this project used only deidentified data from the WHI, it met the criteria for exemption by the Providence Veterans Affairs Medical
Center Institutional Review Board.

WHI Participants
(n=161,808)
WHI Participants enrolled in
Diet Modifcation or active
arms of Hormone Therapy
trials
(n=58,568)
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WHI Participants
in OS or HT Trial
control arms
(n=103,240)
WHI Participants missing
baseline FFQ or with invalid
FFQ data
(n=4,169)

Exposure: Dietary Magnesium
Dietary magnesium intake was derived using a semiquantitative food frequency questionnaire that assessed nutrient intake over the past 3 months.13–15
The nutrient database for the WHI food frequency
questionnaire was adapted from the University of
Minnesota Nutrition Coding Center (Minneapolis,
MN) nutrient database.16 The food frequency questionnaire was administered to all WHI participants at
baseline. We used the baseline unadjusted measurements for dietary magnesium, as well as the residual
method in which dietary magnesium was linearly
regressed on calibrated total energy intake, and the
residuals were used as the independent variable (exposure) in the subsequent analysis.17 Total energy
intake was calibrated using the equation derived
from a study using recovery biomarkers previously
in a subsample of the OS participants, accounting
for age, race, and BMI.18 Both dietary magnesium
intake and residual magnesium intake were divided
into quartiles.
Because participants could also ingest magnesium through oral supplementation, we constructed
a total magnesium variable as a sensitivity analysis, which is the sum of dietary and supplemental
magnesium. Data on magnesium supplement were
obtained through the inventory of the patient’s medication and supplement bottles brought in to the interviewer at baseline clinic visits and coded into a
database through a standardized inventory procedure. In centers without direct access to a computer,
a standardized interviewer-
administered form was
used to collect the information.19,20 Because supplemental intake was measured by a separate methodology, we were not able to use the residual method
for the total magnesium variable.

Outcome: Incident HF Hospitalizations

WHI Participants
with valid FFQ
data
(n=99,071)
WHI Participants with selfreported heart failure at
baseline
(n=1,346)

HF-Free WHI
Participants with
valid FFQ data
(n=97,725)

Figure 1. Flow diagram of WHI participants in the analysis.
FFQ indicates food frequency questionnaire; OS, observational
study; and WHI, Women’s Health Initiative.

The primary outcome was incident hospitalization for
HF, which was ascertained yearly in WHI by medical record abstraction of all self-report hospitalizations and classified by trained adjudicators using
the standardized methodology as previously described.21 Hospitalized HF requiring and/or occurring
during hospitalization required physician diagnosis of
new-onset or worsened HF on the reported hospital
admission and ≥1 of the following 4 criteria: HF diagnosed by physician and receiving medical treatment
for HF; symptoms plus documentation in the current
medical record of a history of an imaging procedure
showing impaired left ventricular (LV) systolic or diastolic LV function; pulmonary edema/congestion on
chest radiograph on the current admission; or dilated
ventricle(s) or “poor” LV or right ventricular function
by echocardiography, radionuclide ventriculography,
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or other contrast ventriculography or evidence of LV
diastolic dysfunction. This method was found to have
a 79% agreement rate comparing central adjudicated
HF and local adjudication.21
In 2010, a subcohort of the WHI OS and hormone
therapy trial oversampled for black and Hispanic participants, were retrospectively evaluated for HFpEF
and HFrEF and then followed until March 31, 2018. Of
the 44 174 participants in this subcohort, 18 745 were
included in a subgroup analysis in this study to determine the etiology of HFpEF or HFrEF (secondary outcome) using the same exclusion criteria as the primary
analysis (Figure S1).

Statistical Analysis
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Descriptive statistics were generated for baseline covariates within quartiles of unadjusted dietary magnesium intake. Specifically, mean and SD were generated
as descriptive statistics for each continuous covariate,
while frequency and percentages were generated for
each categorical covariate.
We used Cox proportional hazards models to estimate the hazard ratios (HRs) of HF for each quartile of
magnesium intake, using the highest intake quartile as
reference. Analyses were conducted first for quartiles
of unadjusted magnesium intake adjusted for total
energy intake, followed by quartiles of residual magnesium intake and then by quartiles of total magnesium intake accounting for supplemental magnesium.
The time to HF event was calculated as the interval
between baseline and incident HF, with censoring at
last follow-up visit or death. Potential selection bias
was accounted for by inverse probability weighting by
membership in the OS or hormone therapy cohorts.
The proportional hazard assumption was checked
by visual examination of the survival curves. Potential
confounders measured at baseline, determined on the
basis of previous knowledge and prior literature, were
included in the multivariable Cox proportional hazards
models if the covariate was determined to be not on
the causal pathway. As such, we used a sequential
approach to analysis in which we constructed 5 submodels, each nested within the next (Table S1). In the
final model, we adjusted for age; race; smoking status; BMI; dyslipidemia; systolic blood pressure; prior
coronary heart disease; atrial fibrillation; heart rate;
hypertension; diabetes mellitus; dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, and calibrated total energy, as these factors may
influence body magnesium handling and storage)22–24;
and medications, such as diuretics (hydrochlorothiazide, furosemide), mineralocorticoid receptor antagonists, angiotensin-
converting enzyme inhibitors or
angiotensin receptor blockers, magnesium containing
laxatives, proton pump inhibitors, or multivitamins, as

Magnesium Intake and Heart Failure in Older Women

these medications may affect magnesium exposure
and potentially the outcome of HF. Sensitivity analyses
were conducted, (1) excluding participants on diuretics and (2) excluding the first year of follow-up from
the analysis to test the robustness of the findings.
Stratified analyses were conducted by race (white versus nonwhite) and by using race-specific quartiles of
magnesium intake.
We tested for the interaction on the multiplicative
scale between dietary magnesium intake with age
and race, as well as with comorbid diseases that
predispose patients to hypomagnesemia (diabetes
mellitus), respectively, and incident HF by including
product terms for each interaction separately, in the
full model. Trend testing across magnesium quartiles was conducted using the median magnesium
value within each quartile. A subgroup analysis was
conducted in the 18 745 participants from the 2010
subcohort to determine the subtype of HF (HFpEF or
HFrEF).
All analyses were conducted in SAS version 9.4
(SAS Institute Inc., Cary, NC).

RESULTS
Among 103 240 participants in the WHI OS or the
placebo arm of the hormone therapy trials, 97 725
were included in the primary analysis. We observed
2153 HF cases over a median follow-up of 8.1 years.
The median dietary magnesium intake across quartiles were 149 mg/day for women in the lowest quartile (mean 144.4±26.9), 212 mg/day (mean 212.3±17.1)
for those in the second quartile, 272 mg/day (mean
273.3±19.3) for the third quartile, and 363 mg/day
(mean 383.1±69.1) for the highest quartile of intake.
Women in the lower quartiles of dietary magnesium
intake were more likely to be aged 70 years or older,
less likely to be white, had lower education and income, more likely to be current smokers, had lower
recreational physical activity and slightly higher systolic blood pressure, and more likely to have hypertension, diabetes mellitus, dyslipidemia, and prior
coronary heart disease. They also had lower dietary
intake of alcohol, calcium, phosphorus, protein, potassium, sodium, vitamin D, and multivitamins and
had lower total energy; and higher use of angiotensin-
converting enzyme inhibitors, diuretics, and proton
pump inhibitors (Table 1).
Compared with those in the highest quartile of unadjusted dietary magnesium intake, women in the
lowest quartile had 1.32 times (95% CI, 1.02–1.71) the
hazard of incident HF in a fully adjusted model (Table 2),
the hazards of which decreased in a linear fashion
with higher dietary magnesium intake (P value for linear trend=0.03). Results were similar using residual
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Table 1. Demographic and Physiologic Characteristics (n=97 725)
Uncalibrated Baseline Dietary Magnesium Intake Quartiles

N

Quartile 1

Quartile 2

Quartile 3

Quartile 4

21 869

25 002

25 475

25 379
363

Magnesium median, mg/d*

149

212

272

HF cases

522

558

551

522

3.10 (3.09–3.12)

2.84 (2.83–2.86)

2.73 (2.72–2.74)

2.59 (2.57–2.60)

63.7 (7.4)

63.6 (7.3)

63.7 (7.3)

63.4 (7.3)

HF incidence†
Age (y) continuous
Mean (SD)
Age (y) categorical
<50–59

6904 (31.6)

7920 (31.7)

7926 (31.1)

8299 (32.7)

60–69

9456 (43.2)

11 042 (44.2)

11 390 (44.7)

11 283 (44.5)

70 to ≥79

5509 (25.2)

6040 (24.2)

6159 (24.2)

5797 (22.8)

Race
American Indian

143 (0.7)

95 (0.4)

88 (0.4)

85 (0.3)

Asian

870 (4.0)

727 (2.9)

553 (2.2)

514 (2.0)

Black

2903 (13.3)

1793 (7.2)

1322 (5.2)

1316 (5.2)

Hispanic

1258 (5.8)

935 (3.8)

690 (2.7)

746 (3.0)

White‡

16 403 (75.0)

21 181 (84.7)

22 577 (88.6)

22 447 (88.4)

Other

292 (1.3)

271 (1.1)

245 (1.0)

271 (1.1)

Less than high school

1844 (8.5)

1234 (5.0)

928 (3.7)

836 (3.3)

High school

7190 (33.2)

6873 (27.7)

6157 (24.4)

5281 (21.0)

Some college

6030 (27.8)

6864 (27.7)

6710 (26.5)

6390 (25.4)

College or greater

6625 (30.6)

9828 (39.6)

11 487 (45.4)

12 665 (50.3)

4334 (19.8)

3684 (14.7)

3169 (12.4)

3295 (13.0)
5383 (21.2)

Education
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Income
<20 000
20 000 to <35 000

5059 (23.1)

5518 (22.1)

5518 (21.7)

35 000 to <50 000

3996 (18.3)

4669 (18.7)

4868 (19.1)

4947 (19.5)

50 000 to <75 000

3543 (16.2)

4675 (18.7)

5039 (19.8)

4959 (19.5)

>75 000

3257 (14.9)

4658 (18.6)

5155 (20.2)

5052 (19.9)

Missing

1680 (7.7)

1798 (7.2)

1726 (6.8)

1743 (6.9)

Smoking status
Never

11 048 (51.3)

12 338 (50.1)

12 573 (50.0)

12 862 (51.4)

Past

8435 (39.2)

10 569 (42.9)

11 157 (44.4)

11 001 (43.9)

Current

2056 (9.6)

1729 (7.0)

1422 (5.7)

1172 (4.7)

27.5 (5.9)

27.2 (5.7)

27.2 (5.8)

27.4 (6.0)

71.5 (17.0)

71.3 (16.5)

71.7 (16.5)

72.9 (17.2)

70 (12.4)

69 (12.3)

69 (11.9)

69 (12.0)

128 (18.2)

127 (17.9)

126 (17.8)

127 (17.7)

75 (9.4)

75 (9.2)

75 (9.3)

75 (9.2)

0.81 (0.09)

0.81 (0.08)

0.80 (0.08)

0.81 (0.08)

13.2 (14.0)

14.3 (14.4)

15.9 (15.2)

Body mass index, kg/m2
Mean (SD)
Weight, kg
Mean (SD)
Heart rate, beats per min
Mean (SD)
Systolic blood pressure, mm Hg
Mean (SD)
Diastolic blood pressure, mm Hg
Mean (SD)
Waist/hip ratio
Mean (SD)

Total energy expenditure from recreational physical activity (METS/wk)
Mean (SD)

10.9 (13.1)

(Continued)

J Am Heart Assoc. 2020;9:e013570. DOI: 10.1161/JAHA.119.0135705

Wu et al

Magnesium Intake and Heart Failure in Older Women

Table 1. Continued
Uncalibrated Baseline Dietary Magnesium Intake Quartiles
Quartile 1

Quartile 2

Quartile 3

Quartile 4

144.4 (26.9)

212.3 (17.1)

273.3 (19.3)

383.1 (69.1)

63.0 (146.3)

71.4 (149.1)

75.0 (153.9)

78.0 (155.1)

207.5 (149.6)

283.7 (150.4)

348.2 (155.3)

461.1 (170.8)

39.9 (12.1)

55.8 (14.1)

69.9 (16.5)

95.9 (27.5)

642.6 (170.3)

939.4 (192.2)

1216.0 (233.4)

1745.7 (467.6)

1553.1 (347.7)

2233.1 (321.8)

2823.3 (381.2)

3840.6 (790.2)

434.5 (182.8)

661.1 (235.3)

877.9 (295.7)

1298.6 (504.2)

2.3 (1.3)

3.4 (1.8)

4.6 (2.4)

6.9 (4.0)

1632.5 (484.7)

2244.1 (583.7)

2775.4 (688.8)

3795.4 (1158.5)

1.83 (4.13)

2.42 (4.66)

2.86 (5.29)

3.12 (6.38)

2220 (263.9)

2255 (261.0)

2282 (267.1)

2332 (282.7)

7555 (35.4)

7993 (32.7)

7856 (31.6)

7835 (31.5)

980 (4.5)

951 (3.8)

900 (3.5)

1033 (4.1)

2049 (9.4)

2374 (9.5)

2297 (9.0)

2138 (8.4)

1546 (7.1)

1625 (6.5)

1581 (6.2)

1535 (6.1)

960 (4.4)

1031 (4.1)

1079 (4.2)

1092 (4.3)

155 (0.7)

196 (0.8)

160 (0.6)

190 (0.8)

1869 (8.6)

1960 (7.8)

1872 (7.4)

1745 (6.9)

7842 (35.9)

10 231 (40.9)

10 996 (43.2)

11 450 (45.1)

3270 (15.0)

3379 (13.5)

3153 (12.4)

3042 (12.0)

26 (0.1)

30 (0.1)

32 (0.1)

30 (0.1)

578 (2.6)

564 (2.3)

491 (1.9)

447 (1.8)

Dietary magnesium intake, mg/d
Mean (SD)
Supplemental magnesium intake, mg/d
Mean (SD)
Total magnesium intake, mg/d
Mean (SD)
Dietary protein intake
Mean (SD)
Dietary phosphorus intake
Mean (SD)
Potassium, mg/d
Mean (SD)
Calcium intake, mg/d
Mean (SD)
Vitamin D, μg/d
Mean (SD)
Sodium intake, mg/d
Mean (SD)
Alcohol, servings/wk
Mean (SD)
Calibrated total energy, kcal/d
Mean (SD)
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Hypertension
Yes
Diabetes mellitus
Yes
Dyslipidemia
Yes
Previous coronary heart disease
Yes
Atrial fibrillation
Yes
Angiotensin receptor blockers
Yes
Angiotensin-converting enzyme inhibitors
Yes
Multivitamin
Yes
Diuretics
Yes
Laxatives containing magnesium
Yes
Proton pump inhibitors
Yes

HF indicates heart failure.
*Range of dietary magnesium (mg/day) by quartiles: quartile 1: 0–181; quartile 2: 182–241; quartile 3: 242–309; quartile 4: 310–1004.
†
Incidence rate per 1000 person-years’ follow-up (95% CI).
‡
266 participants with missing race/ethnicity information were allocated as white.
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Table 2. Hazard Ratio of Incident Hospitalized HF (2005) by Quartiles of Magnesium Intake Using Unadjusted, Residual,
and Total Intake Methods of Magnesium Intake Quantification
Unadjusted Baseline Dietary Magnesium Intake Quartiles* (N=97 725)

N
HF cases
HF incidence†

Q1

Q2

Q3

Q4

21 869

25 002

25 475

25 379

522

558

551

522

3.10 (3.09–3.12)

2.84 (2.83–2.86)

2.73 (2.72–2.74)

2.59 (2.57–2.60)

Hazard Ratio (95% CI)

Unadjusted
Fully adjusted

‡

Q1

Q2

Q3

Q4

P for Trend

1.20 (1.06–1.36)

1.10 (0.98–1.24)

1.06 (0.94–1.19)

Referent

<0.01

1.32 (1.02–1.71)

1.17 (0.96–1.44)

1.08 (0.92–1.27)

Referent

0.03

Residual Baseline Dietary Magnesium Intake (Regression on Calibrated Total Energy Intake)§ (N=97 237)||

N
HF cases
HF incidence†

Q1

Q2

Q3

Q4

22 930

24 004

24 861

25 442

548

509

532

550

3.09 (3.08–3.11)

2.70 (2.68–2.71)

2.70 (2.69–2.72)

2.73 (2.72–2.74)

Hazard Ratio (95% CI)
Q1

Q2

Q3

Q4

P for Trend

Unadjusted

1.13 (1.01–1.27)

0.99 (0.88–1.11)

0.99 (0.88–1.12)

Referent

0.08

Fully adjusted‡

1.31 (1.02–1.67)

1.08 (0.89–1.32)

1.04 (0.89–1.22)

Referent

0.04

Unadjusted Baseline Total Magnesium Intake (Dietary and Supplemental Magnesium)¶ (N=97 725)
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N
HF cases
†

HF incidence

Q1

Q2

Q3

Q4

21 683

24 368

25 555

26 119

556

558

514

525

3.32 (3.30–3.33)

2.91 (2.89–2.92)

2.54 (2.53–2.55)

2.54 (2.53–2.55)

Hazard Ratio (95% CI)
Q1

Q2

Q3

Q4

P for Trend

Unadjusted

1.30 (1.15–1.46)

1.14 (1.01–1.28)

1.00 (0.88–1.13)

Referent

<0.01

Fully adjusted‡

1.26 (1.03–1.56)

1.09 (0.93–1.29)

0.96 (0.84–1.11)

Referent

0.06

HF indicates heart failure; Q, Quartile.
*Range of dietary magnesium (mg/day) by quartiles: quartile 1: 0–181; quartile 2: 182–241; quartile 3: 242–309; quartile 4: 310–1004.
†
Incidence rate per 1000 person-years’ follow-up (95% CI).
‡
Model stratified by observational study/hormone trial membership. Model adjusted for age, race, smoking status, body mass index, dyslipidemia, systolic
blood pressure, prior coronary heart disease, atrial fibrillation, heart rate, hypertension, diabetes mellitus, dietary intake (sodium, potassium, calcium, alcohol,
protein, phosphorus, calibrated total energy), medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, magnesium-
containing laxatives, proton pump inhibitors), and multivitamins.
§
Range of residual dietary magnesium by quartiles: quartile 1: −276 to −68; quartile 2: −67 to −12; quartile 3: −11 to 54; quartile 4: 55–750.
||
Sample size changed because of missingness in some variables used to calibrate total energy intake. Calibrated total energy as a variable was not included
in the analysis using the residual method.
¶
Range of total magnesium intake (mg/day) by quartiles: quartile 1: 0–211; quartile 2: 212–288; quartile 3: 289–382; quartile 4: 383–9275.

magnesium intake (HR, 1.31; 95% CI, 1.02–1.67, lowest versus highest quartile of intake; P-value for linear
trend=0.04) and slightly attenuated in the total magnesium intake accounting for supplemental magnesium
(HR, 1.26; 95% CI, 1.03, 1.56, lowest versus highest
quartile of intake; P value for linear trend=0.06) (Table 2).
Sensitivity analyses excluding participants on diuretic
therapy (fully adjusted HR, 1.24; 95% CI, 0.92–1.67,
lowest versus highest quartile of residual magnesium
intake, n=84 449) or excluding the first year of follow-up

(fully adjusted HR, 1.36; 95% CI, 1.05–1.76, lowest
versus highest quartile of residual magnesium intake,
n=97 077) showed similar HR trends, respectively.
In stratified analyses by race, results remained
consistent among white women (n=82 608), with
an adjusted hazard ratio of 1.43 (95% CI, 1.09–1.88,
lowest versus highest quartile of intake; P value for
linear trend=0.01) but attenuated and nonsignificant
among nonwhite women (n=15 117; P value for linear trend=0.52 unadjusted, and P=0.67 using the
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Table 3. Hazard Ratio of Incident Hospitalized HF (2005) by Race and by Quartiles of Magnesium Intake Using Unadjusted
and Residual Intake Methods of Magnesium Intake Quantification
Unadjusted Baseline Dietary Magnesium Intake Quartiles*
Q1

Q2

Q3

Q4

412 (16 403)

487 (21 181)

497 (22 577)

472 (22 447)

110 (5466)

71 (3821)

54 (2898)

50 (2932)

Number of HF cases (total number)
White
Nonwhite

†

HF incidence (95% CI)
White

3.22 (3.21–3.24)

2.90 (2.89–2.92)

2.76 (2.74–2.77)

2.62 (2.61–2.63)

Nonwhite

2.72 (2.70–2.75)

2.49 (2.46–2.51)

2.50 (2.46–2.53)

2.29 (2.25–2.32)

Adjusted Hazard Ratios (95% CI)‡
Q1

Q2

Q3

Q4

P for
Trend

White

1.43 (1.09–1.88)

1.25 (1.01–1.55)

1.13 (0.95–1.34)

Referent

0.01

Non-White

0.75 (0.35–1.62)

0.79 (0.43–1.46)

0.81 (0.48–1.38)

Referent

0.52

Residual Baseline Dietary Magnesium Intake (Adjusted for Calibrated Energy)§
Q1

Q2

Q3

Q4

432 (17 263)

440 (20 338)

486 (22 023)

501 (22 552)

116 (5667)

69 (3666)

46 (2838)

49 (2890)

# HF cases (total #)
White
Non-White

HF incidence (95% CI)†
White

3.19 (3.18–3.21)

2.73 (2.71–2.74)

2.77 (2.76–2.78)

2.78 (2.77–2.80)

Non-White

2.77 (2.75–2.80)

2.51 (2.48–2.54)

2.16 (2.13–2.19)

2.28 (2.25–2.31)

Adjusted Hazard Ratios (95% CI)‡
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Q1

Q2

Q3

Q4

P for
Trend

White

1.42 (1.09–1.84)

1.14 (0.92–1.40)

1.10 (0.93–1.30)

Referent

0.01

Non-White

0.80 (0.37–1.69)

0.81 (0.45–1.48)

0.76 (0.45–1.30)

Referent

0.67

HF indicates heart failure; Q, Quartile.
*Range of dietary magnesium (mg/day) by quartiles: quartile 1: 0–181; quartile 2: 182–241; quartile 3: 242–309; quartile 4: 310–1004.
†
Incidence rate per 1000 person-years’ follow-up.
‡
Model adjusted for age, smoking status, and traditional risk factors (body mass index, systolic blood pressure, prior coronary heart disease, atrial fibrillation,
heart rate, hypertension, diabetes mellitus, dyslipidemia), dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy
[not included in the analysis using the residual method]), medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics,
magnesium-containing laxatives, proton pump inhibitors), and multivitamins.
§
Range of residual dietary magnesium by quartiles: quartile 1: −276 to −68; quartile 2: −67 to −12; quartile 3: −11 to 54; quartile 4: 55–750.

residual method; Table 3). The interaction terms
between unadjusted magnesium intake (or residual
magnesium) and race (P=0.84), age (P=0.37), and
diabetes mellitus (P=0.65) were not statistically significant. Results remained similar when race-specific
quartiles of magnesium intake were used.
For our subgroup analysis in the 2010 subcohort,
we included 18 745 participants with 985 HF cases
(526 HFpEF, 291 HFrEF, and 168 unknown HF type)
over a median follow-up of 13.2 years (baseline characteristics, Table S2). Lower unadjusted dietary magnesium intake was significantly associated with higher
hazards of HFrEF (HR=1.76 comparing lowest with
highest quartile; 95% CI, 1.03–2.98; P value for linear
trend=0.02) but not HFpEF (HR, 0.74 comparing lowest with highest quartile; 95% CI, 0.49–1.12; P value
for linear trend=0.31; Table S3) in the fully adjusted

model (Figure 2). Results were similar when residual
dietary magnesium intake was used for both HFpEF
(P value for linear trend=0.73 across quartiles) and
HFrEF (P value for linear trend=0.01 across quartiles;
Table S4). Results were no longer significant after
accounting for total magnesium intake (adding magnesium supplements): P value for linear trend=0.24
across quartiles for HFpEF and 0.69 for HFrEF (Table
S5). Sensitivity analyses excluding participants on
diuretic therapy (fully adjusted HRs for HFpEF, 0.88;
95% CI, 0.54–1.41; and for HFrEF, 2.15; 95% CI, 1.19–
3.87; lowest versus highest quartile of residual magnesium intake, n=15 593) or excluding the first year
of follow-up (fully adjusted HRs for HFpEF, 0.99; 95%
CI, 0.66–1.49; and for HFrEF, 1.76; 95% CI, 1.04–2.98;
lowest versus highest quartile of residual magnesium
intake, n=18 657) showed similar results, respectively.
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Figure 2. Hazard ratios (95% CI) of incident hospitalization for HFpEF) and HFrEF in 2010 subcohort by quartiles of
unadjusted and residual magnesium intake, respectively.
Model adjusted for age, smoking status, and traditional risk factors (BMI, systolic blood pressure, prior coronary heart disease,
atrial fibrillation, heart rate, hypertension, diabetes mellitus, dyslipidemia), dietary intake (sodium, potassium, calcium, alcohol,
protein, phosphorus, calibrated total energy [not included in the analysis using the residual method]), medications (angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, diuretics, magnesium-containing laxatives, proton pump inhibitors), and
multivitamins. BMI indicates body mass index; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction.
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In this large, national, multiracial, prospective cohort
study of postmenopausal women, lower dietary intake of magnesium was associated with higher incidence rates of hospitalization for HF. The relationship
between quartiles of dietary magnesium and incident
hospitalization for HF did not vary significantly by race,
age, or presence of diabetes mellitus. In subgroup
analyses, low dietary magnesium was associated only
with incident hospitalized HFrEF but not HFpEF.
To our knowledge, this is one of the first studies
that relates dietary magnesium in postmenopausal
women to incident HF and its subtypes. Our results
expand the previous findings that related higher magnesium intake to lower risk of hospitalizion for HF in
black men and women from the JHS (Jackson Heart
Study)8 to women of other races. Although our results
did not vary significantly by race, an attenuation of
the association between dietary magnesium and HF
to nonsignificant levels were found in the nonwhite
women, which contrast the results in the JHS cohort. This discrepancy could be related to the differential dietary magnesium intake9 and distinct risk of
HF and its subtypes, which has been shown to vary
by race.11 Nonwhite women in our cohort had lower
incidence rates of HF compared with whites, all of
which remained under 1% and could have reduced
our power to detect a statistically significant difference across quartiles of magnesium intake. In contrast, in the JHS cohort, despite a higher magnesium
intake (mean of 181 and 474 mg in the lowest and
highest quartiles of intake, respectively), a younger
age (mean age, 55 years), and a shorter follow-up

time (median, 1837 days), the rates of HF admission
during follow-up remained high, at 1.1% per year. This
is likely attributable to the high prevalence of diabetes
mellitus (22%) and obesity (mean BMI, 31.8 kg/m2) in
the JHS, which conferred the cohort with a high risk
for HF. Taken together, these findings do not show
that the association between magnesium intake and
incident HF significantly vary by race.
Potential mechanisms of the association between
magnesium intake and HF hospitalizations can be several. Low serum and dietary magnesium have been
associated with risk factors of HF, such as coronary
disease,2 left ventricular hypertrophy,25 insulin resistance,3 diabetes mellitus,4 hypertension,5,6 and atrial
fibrillation,7 which over time could lead to HF. The association between dietary magnesium with HFrEF but not
HFpEF in our subgroup analysis is unique and requires
further exploration of mechanisms. A 1-time infusion
of elemental magnesium has been shown to acutely
decreased LV filling pressures,26 while the long-term
effects of magnesium intake on the myocardium is not
known. We postulate that the relationship between
magnesium intake and HFrEF but not HFpEF may
be in part explained by the vascular dilation effects
of magnesium,27 which mirrored the past vasodilator
trials with angiotensin-converting enzyme inhibitors,28
angiotensin receptor blockers,29 and hydralazine and
nitrates30,31 and improved outcomes in patients with
HFrEF but not HFpEF.32,33 Hemodynamically, vasodilation using intravenous nitroprusside improved
stroke volume in HFrEF but in much less magnitude in
HFpEF.34 Similarly, isosorbide did not significantly improve 6-minute walk distance or quality of life in participants with HFpEF.33
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Based on the US Recommended Daily Allowance
of dietary magnesium of 320 mg per day for nonpregnant women >30 years of age, the implications of our
study are large, as ≈75% of postmenopausal women in
this multicenter, multiracial cohort study have a magnesium intake (median, 272 mg for quartile 3) below
Recommended Daily Allowances levels,10 and our results suggest that a quarter of the postmenopausal
women in this cohort are at increased risk of incident
HF on the basis of their dietary magnesium intake. Our
total magnesium intake analysis, which incorporated
magnesium supplements, showed slight attenuation of
the association between dietary magnesium and incident HF and could serve as preliminary data to explore
how supplemental magnesium intake may attenuate
the risk of HF. In addition, the ARIC (Atherosclerosis
Risk in Communities) cohort demonstrated that low
serum magnesium levels were associated with the development of incident HF.35 It is plausible that habitually high intake of magnesium may eventually increase
serum magnesium levels as a reflection of higher body
stores to provide protective effects against HF.36 Future
studies are needed to further explore how magnesium
supplementation may relate to HF risk.
Strengths of the current analysis include data from
a large multiethnic prospective cohort of postmenopausal women that allowed for greater generalizability.
The use of validated dietary data and a high-quality
HF outcome adjudication process would facilitate future replication of our findings. The readjudication
process in the WHI HF subtype cohort also allowed
the secondary analysis examining HFpEF and HFrEF
separately. We used inverse probability weighing to
account for potential selection bias in the WHI cohort
assembly subtypes. There were also limitations to this
study. Despite our careful consideration of potential
confounders, there is always the possibility of residual
and/or unmeasured confounding. The dietary magnesium intake was only quantified at baseline and did not
account for variations in magnesium intake over time
and may have attenuated the results given the long
duration of follow-up. The baseline HF criteria for exclusion into the study sample are based on self-report,
which is low in sensitivity (28%–38%) but high in specificity (96%–97%)37 and may lead to a nonselective misclassification bias and dilute the association between
magnesium intake and incident HF hospitalizations.
Additionally, data on kidney function were limited to
only 10% of our study sample, for which adjustment
for and interaction with kidney function in the analyses
were not feasible. Finally, our analyses were restricted
to women and thus not generalizable to men, but
there has been no evidence that a clinically meaningful
difference by sex exists on the association between
dietary8 or serum magnesium and cardiovascular end
points.35,38–40
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In conclusion, we demonstrated that low dietary
magnesium in a multicenter, multiracial cohort of postmenopausal women was associated with a higher risk
of incident HF, especially HFrEF.
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Table S1. Sub-models of Hazard ratio of incident hospitalized HF (2005) by quartiles (Q) of magnesium
intake using unadjusted, residual and total intake methods of magnesium intake
quantification
Unadjusted baseline dietary magnesium intake quartiles* (N = 97,725)
Q1
Q2
Q3
Q4
N
21,869
25,002
25,475
25,379
HF cases

522

558

551

522

HF incidence†

3.10 (3.09, 3.12)

2.84 (2.83, 2.86)

2.73 (2.72, 2.74)

2.59 (2.57, 2.60)

1.20 (1.06, 1.36)
1.15 (1.02, 1.30)
1.10 (0.97, 1.24)
1.14 (1.00, 1.29)
1.35 (1.04, 1.75)
1.32 (1.02, 1.71)

Hazard Ratio (95% CI)
1.10 (0.98, 1.24)
1.06 (0.94, 1.19)
1.07 (0.95, 1.21)
1.02 (0.90, 1.15)
1.04 (0.92, 1.18)
0.99 (0.88, 1.12)
1.06 (0.94, 1.21)
1.01 (0.89, 1.14)
1.19 (0.97, 1.46)
1.09 (0.92, 1.28)
1.17 (0.96, 1.44)
1.08 (0.92, 1.27)

Unadjusted
Model 1
Model 2
Model 3
Model 4
Model 5

referent
referent
referent
referent
referent
referent

p for trend
<0.01
0.02
0.12
0.04
0.02
0.03
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Residual baseline dietary magnesium intake (regression on calibrated total energy intake)‡ (N=97,237)§
Q1
Q2
Q3
Q4
N
22,930
24,004
24,861
25,442
HF cases

548

509

532

550

HF incidence†

3.09 (3.08, 3.11)

2.70 (2.68, 2.71)

2.70 (2.69, 2.72)

2.73 (2.72, 2.74)

Unadjusted
Model 1
Model 2
Model 3

1.13 (1.01, 1.27)
1.38 (1.23, 1.56)
1.13 (1.00, 1.28)
1.18 (1.04, 1.33)

Hazard Ratio (95% CI)
0.99 (0.88, 1.11)
0.99 (0.88, 1.12)
1.08 (0.95, 1.21)
1.02 (0.90, 1.14)
0.99 (0.88, 1.12)
0.97 (0.86, 1.10)
1.00 (0.88, 1.13)
0.98 (0.86, 1.10)

referent
referent
referent
referent

p for trend
0.08
<0.01
0.09
0.02

Model 4

1.35 (1.06, 1.73)

1.10 (0.91, 1.35)

1.05 (0.90, 1.23)

referent

0.02

Model 5

1.31 (1.02, 1.67)

1.08 (0.89, 1.32)

1.04 (0.89, 1.22)

referent

0.04
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Unadjusted baseline total magnesium intake (dietary and supplemental magnesium)|| (N = 97,725)
Q1
Q2
Q3
Q4
N
21,683
24,368
25,555
26,119
HF cases
556
558
514
525
†
HF incidence
3.32 (3.30, 3.33)
2.91 (2.89, 2.92)
2.54 (2.53, 2.55)
2.54 (2.53, 2.55)
Hazard Ratio (95% CI)
p for trend
Unadjusted
1.30 (1.15, 1.46)
1.14 (1.01, 1.28)
1.00 (0.88, 1.13)
referent
<0.01
Model 1
1.29 (1.14, 1.45)
1.11 (0.98, 1.25)
0.97 (0.86, 1.10)
referent
<0.01
Model 2
1.19 (1.05, 1.34)
1.08 (0.95, 1.22)
0.95 (0.84, 1.07)
referent
<0.01
Model 3
1.19 (1.05, 1.35)
1.06 (0.93, 1.20)
0.94 (0.83, 1.07)
referent
0.01
Model 4
1.29 (1.08, 1.54)
1.11 (0.95, 1.29)
0.97 (0.85, 1.11)
referent
0.01
Model 5
1.26 (1.03, 1.56)
1.09 (0.93, 1.29)
0.96 (0.84, 1.11)
referent
0.06
Models stratified by Observational Study/Hormone Trial membership
Model 1 adjusted for age;
Model 2 adjusted for age, race, smoking status, BMI, and dyslipidemia;
Model 3 was model 2 + prior coronary heart disease, atrial fibrillation, heart rate, hypertension, and diabetes;
Model 4 was Model 3 + dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy);
calibrated total energy as a variable was not included in the analysis using the Residual method
Model 5 (full model) was Model 4 + medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers,
diuretics, Mg containing laxatives, proton pump inhibitors) and multivitamins.
* range of dietary magnesium (mg/day) by quartiles: Q1: 0 to 181; Q2: 182 to 241; Q3: 242 to 309; Q4: 310 to 1004
† incidence rate per 1000 person-years follow up (95% CI)
‡ range of residual dietary magnesium by quartiles: Q1: -276 to -68; Q2: -67 to -12; Q3: -11 to 54; Q4: 55 to 750
§ Sample size changed due to missingness in some variables used to calibrate total energy intake.
|| range of total magnesium intake (mg/day) by quartiles: Q1 0 to 211; Q2 212 to 288; Q3 289 to 382; Q4 383 to 9275

Table S2. Baseline Characteristics of Heart Failure Type, 2010 Sub-cohort (n=18,745).
Un-calibrated baseline dietary magnesium intake quartiles
Q1
Q2
Q3
Q4
N
5905
4755
4082
4003
Magnesium median
143
211
271
366
(mg/day)
HF cases
250
280
233
222
HF incidence*
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Age (years) continuous
mean (SD)
Age (years) categorical
<50 - 59
60 - 69
70 - ≥79
Race
American Indian
Asian
Black
Hispanic
White
Other
Education
<High School
High School
Some College
≥College
Income
<20,000
20,000 - <35,000
35,000 - <50,000

3.55 (3.53, 3.58)

4.60 (4.58, 4.63)

4.05 (4.03, 4.08)

4.09 (4.06, 4.11)

62.4 (7.3)

62.7 (7.4)

63.0 (7.3)

62.8 (7.4)

2218 (37.6)
2584 (43.8)
1103 (18.7)

1742 (36.6)
2047 (43.1)
966 (20.3)

1434 (35.1)
1764 (43.2)
884 (21.7)

1472 (36.8)
1671 (41.7)
860 (21.5)

13 (0.2)
60 (1.0)
2903 (49.2)
1258 (21.3)
1635 (27.7)
27 (0.5)

8 (0.2)
49 (1.0)
1793 (37.7)
935 (19.7)
1945 (40.9)
22 (0.5)

11 (0.3)
39 (1.0)
1322 (32.4)
690 (16.9)
1992 (48.9)
22 (0.5)

10 (0.3)
30 (0.8)
1316 (32.9)
746 (18.7)
1873 (46.8)
26 (0.7)

954 (16.4)
1932 (33.1)
1468 (25.2)
1480 (25.4)

533 (11.3)
1423 (30.3)
1253 (26.7)
1490 (31.7)

390 (9.7)
1128 (27.9)
1064 (26.3)
1461 (36.1)

375 (9.5)
945 (23.9)
1029 (26.0)
1605 (40.6)

1817 (30.8)
1325 (22.4)
986 (16.7)

1100 (23.1)
1158 (24.4)
890 (18.7)

878 (21.5)
1011 (24.8)
713 (17.5)

900 (22.5)
960 (24.0)
777 (19.4)
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50,000 - <75,000
791 (13.4)
719 (15.1)
671 (16.4)
>75,000
479 (8.1)
513 (10.8)
507 (12.4)
Missing
507 (8.6)
375 (7.9)
302 (7.4)
Smoking status
Never
3050 (52.6)
2381 (51.0)
2034 (50.7)
Past
1980 (34.2)
1808 (38.7)
1608 (40.1)
Current
767 (13.2)
481 (10.3)
371 (9.2)
Body Mass Index (kg/m2)
mean (SD)
29.4 (6.4)
29.0 (6.1)
29.0 (6.2)
Weight (kg)
mean (SD)
76.3 (18.2)
75.6 (17.5)
76.0 (17.6)
Heart rate (beats per minute)
70 (12.5)
70 (12.6)
mean (SD)
Systolic Blood Pressure (mm Hg)
mean (SD)
130 (18.3)
129 (17.5)
129 (17.9)
Diastolic Blood pressure (mm Hg)
mean (SD)
77 (9.6)
76 (9.2)
76 (9.5)
Waist/Hip Ratio
mean (SD)
0.82 (0.08)
0.82 (0.08)
0.82 (0.08)
Total energy expenditure from recreational physical activity (METS/week)
mean (SD)
9.2 (12.5)
11.6 (13.6)
12.2 (14.2)
Dietary magnesium intake (mg/day)
mean (SD)
138.9 (29.0)
211.0 (16.9)
272.2 (19.1)
Total magnesium intake (mg/day)
mean (SD)
182.1 (116.7)
265.1 (123.6)
329.3 (130.2)
Potassium (mg/day)
mean (SD)
1462.2 (364.1)
2180.8 (334.5)
2775.9 (404.4)
Calcium intake (mg/day)
mean (SD)
400.3 (175.5)
632.1 (230.3)
838.9 (294.9)
Dietary protein intake (grams)
mean (SD)
39.56 (12.9)
56.9 (15.6)
72.0 (18.7)
Dietary phosphorus intake (mg)
mean (SD)
624.6 (178.3)
941.1 (204.1)
1216.8 (249.2)

617 (15.4)
474 (11.8)
275 (6.9)
2053 (52.4)
1574 (40.1)
295 (7.5)
29.4 (6.5)
77.3 (18.5)
70 (11.5)
129 (17.7)
76 (9.4)
0.82 (0.08)
14.0 (15.4)
388.4 (75.4)
447.2 (147.4)
3862.4 (880.5)
1272.8 (530.7)
101.9 (32.6)
1791.7 (516.3)
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Vitamin D (mcg/d)
mean (SD)
2.1 (1.3)
3.4 (1.8)
Sodium intake (mg/day)
mean (SD)
1618.5 (524.3)
2301.4 (644.4)
Alcohol (servings/wk)
mean (SD)
1.27 (3.66)
1.80 (4.28)
Calibrated total energy (kcal/day)
mean (SD)
2272 (284.5)
2301 (280.0)
Hypertension
Yes
2431 (43.1)
1772 (39.2)
Diabetes mellitus
Yes
490 (8.3)
363 (7.7)
Dyslipidemia
Yes
485 (8.2)
434 (9.1)
Previous coronary heart disease
Yes
467 (7.9)
368 (7.7)
Atrial fibrillation
Yes
249 (4.2)
161 (3.4)
Angiotensin receptor blockers
Yes
41 (0.7)
36 (0.8)
Angiotensin converting enzyme inhibitors
Yes
601 (10.2)
447 (9.4)
Multivitamin
Yes
1607 (27.2)
1534 (32.3)
Diuretics
Yes
1074 (18.2)
821 (17.3)
Laxatives containing magnesium
Yes
15 (0.3)
8 (0.2)
Proton pump inhibitors
Yes
129 (2.2)
112 (2.4)
* incidence rate per 1000 person-years follow up (95% CI)
HF = heart failure, SD = Standard Deviation

4.4 (2.4)

6.8 (4.3)

2875.0 (774.7)

4094.6 (1394.3)

2.31 (5.43)

2.73 (7.04)

2326 (284.1)

2382 (313.5)

1464 (37.9)

1452 (38.3)

286 (7.0)

311 (7.8)

371 (9.1)

303 (7.6)

306 (7.5)

263 (6.6)

149 (3.7)

158 (4.0)

20 (0.5)

20 (0.5)

335 (8.2)

298 (7.4)

1398 (34.3)

1442 (36.0)

621 (15.2)

586 (14.6)

5 (0.1)

3 (0.1)

70 (1.7)

60 (1.5)

Table S3. Hazard ratio of incident hospitalized preserved & reduced heart failure in 2010 sub-cohort by quartiles (Q) of unadjusted
magnesium intake.
Heart Failure with preserved Ejection Fraction (HFpEF)
Unadjusted baseline dietary magnesium intake
Q2
Q3
Q4
4755
4082
4003
155
133
119

N
HFpEF cases

Q1
5905
121

HFpEF incidence*

1.81 (1.80, 1.82)

2.63 (2.61, 2.64)

0.85 (0.70, 1.02)
0.74 (0.49, 1.12)

HR (95% CI)
1.19 (1.00, 1.42)
1.02 (0.86, 1.22)
1.09 (0.80, 1.49)
0.97 (0.75, 1.24)

Unadjusted
Fully-Adjusted

2.30 (2.29, 2.32)

2.24 (2.23, 2.26)
referent
referent

p for trend
0.37
0.31

Heart Failure with reduced Ejection Fraction (HFrEF)
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N
HFrEF cases

Q1
5905
86

HFrEF incidence*

1.18 (1.17, 1.19)

Unadjusted baseline dietary magnesium intake
Q2
Q3
Q4
4755
4082
4003
72
71
64
1.18 (1.17, 1.19)

1.28 (1.27, 1.28)

1.13 (1.13, 1.14)

HR (95% CI)
p for trend
referent
Unadjusted
1.08 (0.84, 1.38)
1.06 (0.83, 1.36)
1.13 (0.88, 1.44)
0.65
referent
Fully-Adjusted
1.76 (1.03, 2.98)
1.60 (1.06, 2.43)
1.25 (0.88, 1.75)
0.02
Model adjusted for age, race, smoking status, BMI, and dyslipidemia, systolic blood pressure, prior coronary heart disease, atrial fibrillation,
heart rate, hypertension, and diabetes, dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy),
medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, magnesium containing laxatives, proton pump
inhibitors) and multivitamins.
* incidence rate per 1000 person-years follow up (95% CI)

Table S4. Hazard ratio of incident hospitalized preserved & reduced heart failure in 2010 sub-cohort by quartiles (Q) of residual
magnesium intake after regression on calibrated total energy intake
Heart Failure with preserved Ejection Fraction (HFpEF)
Residual baseline dietary magnesium intake (adjusted for calibrated energy)
Q1
Q2
Q3
Q4
N*
6337
4528
3951
3868
HFpEF cases
140
129
148
109
HFpEF incidence†
Unadjusted
Fully-Adjusted

1.95 (1.94, 1.96)

2.24 (2.23, 2.25)

2.69 (2.67, 2.70)

0.94 (0.79, 1.13)
0.97 (0.65, 1.46)

HR (95% CI)
1.06 (0.88, 1.27)
1.25 (1.04, 1.49)
1.07 (0.78, 1.47)
1.21 (0.94, 1.55)

2.14 (2.13, 2.16)
referent
referent

p for trend
0.30
0.73
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Heart Failure with reduced Ejection Fraction HFrEF
Residual baseline dietary magnesium intake (adjusted for calibrated energy)
Q1
Q2
Q3
Q4
N*
6337
4528
3951
3868
HFrEF cases
84
76
67
64
HFrEF incidence†

1.07 (1.06, 1.07)

1.33 (1.32, 1.34)

1.23 (1.22, 1.24)

1.17 (1.17, 1.18)

HR (95% CI)
p for trend
referent
Unadjusted
0.93 (0.73, 1.20)
1.15 (0.90, 1.46)
1.05 (0.82, 1.36)
0.09
referent
Fully-Adjusted
1.81 (1.08, 3.05)
1.90 (1.26, 2.86)
1.28 (0.91, 1.80)
0.01
Model adjusted for age, race, smoking status, BMI, and dyslipidemia, systolic blood pressure, prior coronary heart disease, atrial fibrillation,
heart rate, hypertension, and diabetes, dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy),
medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, Mg containing laxatives, proton pump
inhibitors) and multivitamins.
* Sample size changed due to missingness in some variables used to calibrate total energy intake.
† incidence rate per 1000 person-years follow up (95% CI)

Table S5. Hazard ratio of incident hospitalized preserved & reduced heart failure in 2010 sub-cohort by quartiles (Q) of total
magnesium intake (accounting for magnesium supplements).
Heart Failure with preserved Ejection Fraction (HFpEF)
Unadjusted total dietary magnesium intake
Q2
Q3
4819
4100
131
147

N
HFpEF cases

Q1
6137
146

HFpEF incidence*

2.13 (2.12, 2.14)

2.11 (2.10, 2.12)

1.08 (0.90, 1.30)
1.25 (0.89, 1.76)

HR (95% CI)
1.03 (0.85, 1.24)
1.28 (1.07, 1.54)
1.11 (0.85, 1.45)
1.25 (1.01, 1.56)

Unadjusted
Fully-Adjusted

2.66 (2.64, 2.68)

Q4
3689
104

2.07 (2.06, 2.09)
referent
referent

p for trend
0.82
0.24

Heart Failure with reduced Ejection Fraction HFrEF

Downloaded from http://ahajournals.org by on March 31, 2020

N
HFrEF cases

Q1
6137
86

HFrEF incidence*

1.11 (1.10, 1.12)

Unadjusted total dietary magnesium intake
Q2
Q3
4819
4100
83
65
1.34 (1.33, 1.35)

1.15 (1.14, 1.16)

Q4
3689
59

1.17 (1.16, 1.17)

HR (95% CI)
p for trend
referent
Unadjusted
0.99 (0.77, 1.27)
1.16 (0.91, 1.47)
0.98 (0.76, 1.27)
0.76
referent
Fully-Adjusted
1.05 (0.67, 1.65)
1.13 (0.80, 1.60)
0.90 (0.67, 1.21)
0.69
Model adjusted for age, race, smoking status, BMI, and dyslipidemia, systolic blood pressure, prior coronary heart disease, atrial fibrillation,
heart rate, hypertension, and diabetes, dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy),
medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, Mg containing laxatives, proton pump
inhibitors) and multivitamins.
* incidence rate per 1000 person-years follow up (95% CI)

Figure S1.
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